Zydus Cadila gets USFDA nod for skin ointment
New Delhi: Drug firm Zydus Cadila said it has received approval from the US health regulator to market Clobetasol Propionate ointment, used to treat a range of skin conditions, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, Zydus Cadila said in a statement.
The ointment will be manufactured at the company's Ahmedabad-based facility. The Zydus group has now more than 165 product approvals.
Stock of Cadila Healthcare, the listed entity of the Zydus group, was trading 0.32 per cent up at Rs 492.95 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd